Asia Pacific has shown significant increase in Immuno-oncology trials between 2017 and 2021 and contributes to more than a third of the global clinical development of Immune-oncology drugs.
一家致力於推進新藥開發進程的國際性受託研究機構 (CRO) 和科學諮詢合作夥伴
立足臨床試驗,護航人類健康未來
協同合作共進,科創驅動前行
深耕產業標竿,鑄就卓越口碑
深耕臨床科研數十載,引領產業發展標竿
Asia Pacific has shown significant increase in Immuno-oncology trials between 2017 and 2021 and contributes to more than a third of the global clinical development of Immune-oncology drugs.